Royal Bank of Canada Reaffirms “Outperform” Rating for BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals (NASDAQ:BCRX)‘s stock had its “outperform” rating reissued by investment analysts at Royal Bank of Canada in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $11.00 target price on the biotechnology company’s stock. Royal Bank of Canada’s price target would indicate a potential upside of 61.29% from the stock’s previous close.

Several other analysts also recently issued reports on BCRX. Needham & Company LLC reaffirmed a “buy” rating and issued a $15.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Thursday. Evercore ISI raised their price target on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a report on Monday, January 13th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. JMP Securities reissued a “market outperform” rating and issued a $18.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Finally, Wedbush assumed coverage on BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They set an “outperform” rating and a $15.00 target price on the stock. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, BioCryst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $15.57.

BioCryst Pharmaceuticals Trading Up 6.4 %

Shares of NASDAQ BCRX opened at $6.82 on Friday. The stock has a fifty day moving average price of $7.96 and a 200 day moving average price of $7.74. BioCryst Pharmaceuticals has a 12-month low of $4.03 and a 12-month high of $9.50. The company has a market cap of $1.43 billion, a P/E ratio of -11.18 and a beta of 1.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The firm had revenue of $131.50 million during the quarter, compared to analyst estimates of $126.64 million. The business’s quarterly revenue was up 40.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.28 EPS. On average, sell-side analysts forecast that BioCryst Pharmaceuticals will post -0.36 EPS for the current fiscal year.

Institutional Trading of BioCryst Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of BCRX. Vanguard Group Inc. increased its holdings in shares of BioCryst Pharmaceuticals by 7.8% in the 4th quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company’s stock valued at $164,616,000 after acquiring an additional 1,583,826 shares during the last quarter. Eversept Partners LP boosted its holdings in BioCryst Pharmaceuticals by 269.9% in the fourth quarter. Eversept Partners LP now owns 1,980,312 shares of the biotechnology company’s stock worth $14,892,000 after purchasing an additional 1,444,907 shares during the period. Hillsdale Investment Management Inc. increased its stake in BioCryst Pharmaceuticals by 65,213.3% during the fourth quarter. Hillsdale Investment Management Inc. now owns 542,100 shares of the biotechnology company’s stock valued at $4,077,000 after purchasing an additional 541,270 shares during the last quarter. Balyasny Asset Management L.P. acquired a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth $3,983,000. Finally, Norges Bank acquired a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth $3,947,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.